Delhivery Regulatory Approval

Board Meeting Date

Delhivery Board Meeting Date

Delhivery Limited will hold a board meeting on October 30, 2026, to approve unaudited financial results for the quarter and half-year ended September 30, 2026.

Other Announcement

Delhivery Other Announcement

Delhivery Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.

Business Update

Delhivery Business Update

Delhivery won the Golden Peacock Award for Excellence in Corporate Governance 2026 in the Logistics sector. The recognition was awarded by the Institute of Directors, India.

Employee Stock Options

Delhivery Employee Stock Options

Delhivery Ltd allotted 2,28,116 equity shares upon the exercise of vested stock options under its ESOP plans. The allotment increases the company's paid-up share capital.

Value

₹0.07 Cr

Employee Stock Options

Delhivery Employee Stock Options

Delhivery Ltd has granted 52,600 stock options to eligible employees under its ESOP 2012 plan. This action is part of the company's ongoing employee incentive scheme.

Employee Stock Options

Delhivery Employee Stock Options

Delhivery Limited has granted 9,00,000 stock options under its ESOP-2021 plan. The options are exercisable at Re. 1 per share subject to vesting conditions.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.